Abstract:Dengue virus (DENV) is the most common vector-borne viral disease, with nearly 400 million worldwide infections each year concentrated in the tropical and subtropical regions of the world. Severe dengue complications are often associated with a secondary heterotypic infection of one of the four circulating serotypes. In this scenario, humoral immune responses targeting cross-reactive, poorly neutralizing epitopes can lead to increased infectivity of susceptible cells via antibody-dependent enhancement (ADE). In this way, antibodies produced in response to infection or vaccination are capable of contributing to enhanced disease in subsequent infections. Currently, there are no available therapeutics to combat DENV disease, and there is an urgent need for a safe and efficacious vaccine. Here, we developed a nucleotide-modified mRNA vaccine encoding the membrane and envelope structural proteins from DENV serotype 1 encapsulated in lipid nanoparticles (prM/E mRNA-LNP). Vaccination of mice elicited robust antiviral immune responses comparable to viral infection, with high levels of neutralizing antibody titers and antiviral CD4 + and CD8 + T cells. Immunocompromised AG129 mice vaccinated with the prM/E mRNA-LNP vaccine were protected from a lethal DENV challenge. Vaccination with either a wild-type vaccine or a vaccine with mutations in the immunodominant fusion loop epitope elicited equivalent humoral and cell-mediated immune responses. Neutralizing antibodies elicited by the vaccine were sufficient to protect against a lethal challenge. Both vaccine constructs demonstrated serotype-specific immunity with minimal serum cross-reactivity and reduced ADE in comparison to a live DENV1 viral infection. IMPORTANCE With 400 million worldwide infections each year, dengue is the most common vector-borne viral disease. Forty percent of the world's population is at risk, with dengue experiencing consistent geographic spread over the years. With no therapeutics available and vaccines performing suboptimally, the need for an effective dengue vaccine is urgent. Here, we develop and characterize a novel mRNA vaccine encoding the dengue serotype 1 envelope and premembrane structural proteins that is delivered via a lipid nanoparticle. Our DENV1 prM/E mRNA-LNP vaccine induces neutralizing antibody and cellular immune responses in immunocompetent mice and protects an immunocompromised mouse from a lethal DENV challenge. Existing antibodies against dengue can enhance subsequent infections via antibody-dependent enhancement (ADE). Importantly our vaccine induced only serotype-specific immune responses and did not induce ADE.

Enhancing Dengue Virus Maturation Using a Stable Furin Over-Expressing Cell Line.

Development of Tobacco necrosis virus A as a vector for efficient and stable expression of FMDV VP1 peptides.

Structure of the Immature Dengue Virus at Low Ph Primes Proteolytic Maturation

The Flavivirus Precursor Membrane-Envelope Protein Complex: Structure and Maturation

Enhancing Dengue Virus Production and Immunogenicity with CelcradleTM Bioreactor: A Comparative Study with Traditional Cell Culture Methods

Construction and Rescue of a DNA-Launched DENV2 Infectious Clone

Using a Virion Assembly-Defective Dengue Virus As a Vaccine Approach

An evolutionarily conserved ubiquitin ligase drives infection and transmission of flaviviruses

Obstruction of dengue virus maturation by Fab fragments of the 2H2 antibody.

NS1 Protein N-Linked Glycosylation Site Affects the Virulence and Pathogenesis of Dengue Virus

Evaluating HIV-1 Infectivity and Virion Maturation Across Varied Producer Cells with a Novel FRET-Based Detection and Quantification Assay

Dengue virus-free defective interfering particles have potent and broad anti-dengue virus activity

Structure of Dengue Virus: Implications for Flavivirus Organization, Maturation, and Fusion

Development of viable TAP-tagged dengue virus for investigation of host-virus interactions in viral replication

Characterization Of A Candidate Tetravalent Vaccine Based On 2 '-O-Methyltransferase Mutants

Conformational changes of the flavivirus E glycoprotein.

Construction of a Dengue NanoLuc Reporter Virus for in Vivo Live Imaging in Mice

Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody

A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses

Influence of Pr-M Cleavage on the Heterogeneity of Extracellular Dengue Virus Particles